Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses - ScienceDirect

Cureus, COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library

Vaccines, Free Full-Text

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

Monovalent and bivalent mRNA vaccines encoding ancestral, Beta and

Protein-based SARS-CoV-2 spike vaccine booster increases cross- neutralization against SARS-CoV-2 variants of concern in non-human primates

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques - ScienceDirect

A case for updating COVID vaccines with beta variant spike sequences

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants, Journal of Biomedical Science